Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Bimekizumab, Atc L04Ac21 (Obo) For The Period 01.10.2024 - 30.09.2026

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  MT Ref Id - 91056234

  Document Type - Tender Notices

Description - Description: Scope of procurementBrief descriptionSection 130a paragraph 8 of the Social Code Book V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be dispensed at the expens e of the statutory health insurance companies. With regard to the relevant legal provisions for the award of public contracts, a regular process of active substance-related, formal procurement procedures takes place by DAK-Gesundheit in accordance with the regulations of Part 4 of the GWB. For drugs for the above-mentioned active substance, Bimekizumab, ATC L04AC21, which are to be specified by the bidder in Annex 2 to the contract, DAK-Gesundhei

Mt Ref Id - 91056234

Deadline - Aug 05, 2026